Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM by Sundar Jagannath, Rafat Abonour, Brian G. M. Durie, Mohit Narang, Howard R. Terebelo, Cristina J. Gasparetto, Kathleen Toomey, James W. Hardin, Lynne Wagner, Amit Agarwal, Shankar Srinivasan, Amani Kitali, E. Dawn Flick, Michael Sturniolo, and Robert M. Rifkin BloodAdv Volume 2(13):1608-1615 July 10, 2018 © 2018 by The American Society of Hematology

Sundar Jagannath et al. Blood Adv 2018;2:1608-1615 © 2018 by The American Society of Hematology

Study design. Study design. Patients in cohort 1 who received induction therapy and ASCT were included and analyzed by first-line post-ASCT maintenance therapy. The exploratory analysis was performed on groups with adequate sample sizes (lenalidomide maintenance therapy and no maintenance therapy). SCT, stem cell transplantation. Sundar Jagannath et al. Blood Adv 2018;2:1608-1615 © 2018 by The American Society of Hematology

Survival for patients treated with lenalidomide vs no maintenance therapy. Survival for patients treated with lenalidomide vs no maintenance therapy. Patients receiving post-ASCT lenalidomide maintenance therapy had improved (A) PFS (P < .001) and (B) OS (P = .005) compared with those who did not receive maintenance therapy. Analysis was adjusted for covariates of ECOG performance status, serum creatinine level, treatment with a novel agent, treatment with lenalidomide, treatment with bortezomib, and triplet treatment during first-line induction therapy. Sundar Jagannath et al. Blood Adv 2018;2:1608-1615 © 2018 by The American Society of Hematology

Exploratory survival subgroup analysis for lenalidomide vs no maintenance therapy. Exploratory survival subgroup analysis for lenalidomide vs no maintenance therapy. Improvements in (A) PFS and (B) OS observed with lenalidomide maintenance therapy were generally similar across all subgroups. Sundar Jagannath et al. Blood Adv 2018;2:1608-1615 © 2018 by The American Society of Hematology

PFS (unadjusted) and OS (unadjusted) by IMWG risk criteria. PFS (unadjusted) and OS (unadjusted) by IMWG risk criteria. (A) PFS and (B) OS were similar among IMWG high- and standard-risk patients receiving lenalidomide (Len) maintenance therapy, but poorest in high-risk patients with no maintenance therapy. Sundar Jagannath et al. Blood Adv 2018;2:1608-1615 © 2018 by The American Society of Hematology

Second PFS for lenalidomide vs no maintenance therapy. Second PFS for lenalidomide vs no maintenance therapy. Median second PFS was similar between the 2 groups. Only patients who had first progression were considered for this analysis. Sundar Jagannath et al. Blood Adv 2018;2:1608-1615 © 2018 by The American Society of Hematology